Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $5.9 million.

  • Gyre Therapeutics' Income from Continuing Operations rose 10784.31% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 11279.92%. This contributed to the annual value of $16.9 million for FY2024, which is 11957.5% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Income from Continuing Operations of $5.9 million as of Q3 2025, which was up 10784.31% from $1.6 million recorded in Q2 2025.
  • Gyre Therapeutics' Income from Continuing Operations' 5-year high stood at $51.6 million during Q2 2022, with a 5-year trough of -$101.8 million in Q4 2023.
  • Its 5-year average for Income from Continuing Operations is -$7.5 million, with a median of $1.6 million in 2025.
  • As far as peak fluctuations go, Gyre Therapeutics' Income from Continuing Operations plummeted by 45319.52% in 2021, and later skyrocketed by 35909.27% in 2022.
  • Over the past 5 years, Gyre Therapeutics' Income from Continuing Operations (Quarter) stood at -$20.3 million in 2021, then crashed by 41.75% to -$28.8 million in 2022, then crashed by 253.66% to -$101.8 million in 2023, then skyrocketed by 99.57% to -$433000.0 in 2024, then skyrocketed by 1470.9% to $5.9 million in 2025.
  • Its Income from Continuing Operations was $5.9 million in Q3 2025, compared to $1.6 million in Q2 2025 and $3.7 million in Q1 2025.